It is a Fab fragment of a humanized monoclonal antibody directed against the glycoprotein IIb/IIIa. The latter is a platelet surface integrin. It is a receptor for fibrinogen which binds platelets to each other causing aggregation. By inhibiting the receptor, abciximab acts as a potent antiplatelet agent. Indications: 1) myocardial ischemia, 2) percutaneous coronary intervention. Dose: 1) For M.I - initially an I.V bolus of 0.25 mg/kg over 5 min followed by 0.125 µg/kg/min (to a maximum of 10 µg/min) for 12 hours. 2) For P.C.I - initially, 0.25 mg/kg I.V bolus over 5 min 20-60 min prior to angioplasty followed by 0.125 µg/kg/min (to a maximum of 10 µg/min) for next 12 hours. Contraindications: 1) bleeding disorder or use of anticoagulant within 7 days, 2) CVA within 2 years, 3) known allergy to this product, 4) major trauma or surgery within 6 weeks, 5) severe uncontrolled hypertension, 6) active internal bleeding, 7) thrombocytopenia i.e pla